The Future Of Clinical Trials: 7 Trends Redefining Functional Service Provider (FSP) Models By 2030

By Amanda Heller, Sr Director of FSP Solutions, LabConnect

Clinical trials by 2030 will operate in a landscape reshaped by advanced modalities, tightening global regulation, and decentralized execution models that few sponsors can staff internally. Amanda Heller, Sr. Director of FSP Solutions at LabConnect, outlines seven forces redefining Functional Service Provider partnerships, from consolidation toward fewer strategic vendors to AI-driven compliance, protocol digitization under ICH M11, and outcome-linked commercial models replacing FTE pricing. As quality expectations rise under ICH E6(R3) and regulatory frameworks shift across regions including the EU and Asia-Pacific, sponsors who fail to embed adaptable, technology-enabled FSP models risk losing ground on speed, cost, and compliance.

Explore the trends set to determine which partnerships thrive as clinical development enters its next phase.